Key Takeaways
- Export rout drives top-line miss: Revenue fell 19% YoY to ₹206 cr as export sales halved, overwhelmed by channel destocking and Chinese oversupply; domestic formulations grew and now provide the floor.
- ₹22 cr inventory hit resets the base: Stock revaluation on raw materials and finished goods wiped ~500 bps from EBITDA margin in H1; management says the bleed is over, with only 1–2% residual risk left.
- Margin recovery is the near-term thesis: EBITDA margin should bounce back to 16–18% over the next two quarters, and management targets 20–22% on newer products from next year onward, though it walked back any hope of holding 50% gross margins.
- Capacity doubling is underway but undated: Two plants (Sandila adjacent land + Hamirpur) plus a new asset-light registration subsidiary are being built; management is "hopeful of doing wonders in 2–3 years" but refused to pin a timeline to the capacity doubling.
- What to watch next quarter: Whether the promised 16–18% EBITDA margin materializes, any sign that international destocking is ending (management thinks 1–2 more quarters), and progress on Hamirpur's first-block commissioning targeted for Q4 FY24.
Revenue Breakdown: Export Collapse, Domestic Resilience
- Export revenue halved: Fell from ₹122 cr to ₹62 cr YoY as international markets stayed bleak, burdened by high channel inventory built up during the COVID-era container crisis and fresh low-cost supply pouring out of China.
- Domestic business grew 9% YoY: Rose from ₹128 cr to ₹140 cr, driven by robust farm-level demand and an expanding distributor network now at ~5,000 pan-India outlets.
- Technicals still dominate the mix: At 77% of revenue, the technical segment carries the export exposure and the destocking pain; management flagged a $4.2 bn opportunity from 19 molecules going off patent.
- End-market demand is intact but invisible: Farmers are buying and applying product, yet a large overhang of inventory must be consumed before orders flow back to manufacturers; destocking is expected to persist for another one to two quarters.
Anand Agarwal: "One thing I can tell you that we can't give you as a particular at this moment, any concrete time frame, but our team, and we are quite hopeful that in coming 2-3 years, we are going to do wonders."
Margin Walk: The Inventory Hole and the Recovery Path
- ₹22 cr stock revaluation drove the margin miss: Raw material and finished goods prices fell substantially, forcing a write-down that cost roughly 500 bps of EBITDA margin on ₹400 cr of H1 sales; management characterized the remaining old inventory as "very small."
- Sequential EBITDA improvement already visible: EBITDA of ₹31 cr grew 19% QoQ despite the top-line headwinds, suggesting the worst of the inventory drag is passing.
- Near-term margin guide: 16–18% EBITDA: Management expects margins to recover to that band over the next two quarters as inventory losses fade and operating leverage returns.
- Gross margin target reset lower: Earlier high margins were an artifact of constrained Chinese supply; now that supply has normalized, the company is targeting 43–44% gross margin next year, down from the 50%+ levels some analysts had modeled.
- Newer-product EBITDA ambition: 20–22%: Not achievable this year given the difficult environment, but management is planning for that range from next year onward.
- Pricing power varies sharply by molecule value: On low-priced products ($5/kg), customers do not push back on margin; on high-priced ones ($60/kg), MNCs resist a $12 absolute margin, compressing percentage returns at the premium end.
Dheeraj Jain: "Sir, what happens, if we want to take a 20% margin on a price for $60, it will be $12. So $12, they will say it is too much. The customers, the MNCs, when they calculate the cost of the raw material and the conversion costs and when they want the margin $12, they feel like we are charging too much, that's what they feel, in general. But in a low-value product like $5, then they don't question so much."
Capacity Build-Out: Sandila, Hamirpur and the Registration Subsidiary
- Sandila adjacent land acquired: The company bought land next to its existing Sandila plant to facilitate expansion; an additional block for intermediates and another for technical are targeted for H2 FY24, adding 2,000 metric tonnes of capacity by Q4 FY24.
- Hamirpur plant: first block by fiscal year-end: Construction is in progress on the first molecule; commissioning is expected in the last quarter of this financial year, with engineering underway for subsequent molecules.
- Total capacity doubling is the ambition: Installed capacity of 26,000 metric tonnes per annum is expected to double once the Sandila and Hamirpur blocks come online, but management declined to give a concrete timeline for the full doubling.
- New subsidiary: asset-light registration play: Shalvis Specialties Limited will identify molecules, prepare dossiers, seek registrations, and market formulations and technicals abroad under a B2B and B2C model, explicitly inspired by Sharda Cropchem; the logic is that registration, once secured, assures future business even if the initial process is slow.
- Capex fully internally funded: ₹50 cr planned for IPL and ₹60 cr for Shalvis Specialties in FY24, both to be met from internal accruals.
Dheeraj Jain: "If we register once, initially it takes a little more time, but if you register once, then the business is assured. Because anyhow whenever we want to sell, we've got to increase our overall portfolio and revenues, then we need to register and increase our product portfolio."
Geographic and Portfolio Expansion
- Latin America is the priority geography: The company is present in Brazil (via 2–3 customers, no own subsidiary), Mexico, Uruguay, Paraguay, Peru, Colombia and Cuba; registration work is ongoing for more products, and management recently visited Brazil to accelerate that effort.
- Domestic formulation distribution deepening: The formulation business is growing every year, with the distributor count now at ~5,000 and efforts underway to increase presence across all Indian states.
- Cross-leveraging export molecules for India: Management is looking at opportunities to develop data on molecules manufactured for export that also have good market potential domestically, then start selling them in India.
- Export formulation margins are higher but volumes low: The company acknowledged the margin premium in export formulations but noted the volume base is still small.
- One new small molecule added: Recently added to the portfolio, though management did not quantify its contribution.
Succession and Governance
- Next generation joins the board: Mr. Vishal Swarup Agarwal and Mr. Vishwas Swarup Agarwal, sons of the Chairman, were appointed as Non-Executive Directors as part of a strategic succession plan.
Dheeraj Jain: "This marks a momentous occasion for us, igniting the path towards an exciting leap into the future of exponential growth."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin recovery | Recover to 16–18% range | Next 2 quarters |
| Newer-product EBITDA | Achieve 20–22% EBITDA margin | From next year onward |
| Gross margin target | 43–44% gross margin | Next year |
| Residual inventory loss | No further material loss beyond 1–2% | From here onward |
| Sandila capacity addition | 2,000 metric tonnes (1 intermediate block + 1 existing product capacity increase) | By Q4 FY24 |
| Hamirpur first block commissioning | First molecule production start | Last quarter of this financial year |
| International destocking | Destocking to persist | Another 1–2 quarters |
| FY24 capex | ₹50 cr (IPL) + ₹60 cr (Shalvis Specialties), funded via internal accruals | FY24 |
Key Metrics
| Metric | Q2 FY24 |
|---|---|
| Total revenue | ₹206 cr, vs ₹253 cr in Q2 FY23 |
| EBITDA | ₹31 cr, sequential growth of 19% |
| EBITDA margin | 15% |
| Net profit | ₹20 cr |
| PAT margin | 9.5% |
| Export revenue | ₹62 cr, vs ₹122 cr in Q2 FY23 |
| Domestic revenue | ₹140 cr, vs ₹128 cr in Q2 FY23 |
| Technicals revenue | ₹115 cr |
| Formulation revenue | ₹87 cr |
| Inventory loss impact on EBITDA margin | ~500 bps decline in H1 FY24, from total ₹22 cr inventory loss on sales of ₹400 cr |
| Cash and cash equivalents | ₹168 cr at quarter end |
| Capex spent in H1 FY24 | ₹30 cr |
| Capex planned for FY24 (IPL) | ₹50 cr |
| Capex planned for FY24 (Shalvis Specialties) | ₹60 cr |
| Total installed capacity | 26,000 metric tonnes per annum |
| Technicals and intermediates capacity addition planned | 2,000 metric tonnes, taking total to 23,200 metric tonnes, expected by Q4 FY24 |
| Technical segment revenue share | 77% of total revenue |
| Domestic formulation distributors | ~5,000 across pan-India |
| Latin America share of Technical sales | 8% to 10% |
| EBITDA margin expectation for next year onwards | 20% to 22% |
| Gross margin target for next year | 43% to 44% |